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Topical Vaccination with Functionalized Particles
Targeting Dendritic Cells
Renato B. Baleeiro1,2, Karl-Heinz Wiesmu¨ller3, Yoran Reiter4, Barbara Baude5, Lars Da¨hne5, Alexa Patzelt1,
Ju¨rgen Lademann1, Jose´ A. Barbuto2 and Peter Walden1
Needle-free vaccination, for reasons of safety, economy, and convenience, is a central goal in vaccine
development, but it also needs to meet the immunological requirements for efficient induction of prophylactic
and therapeutic immune responses. Combining the principles of noninvasive delivery to dendritic cells (DCs)
through skin and the immunological principles of cell-mediated immunity, we developed microparticle-based
topical vaccines. We show here that the microparticles are efficient carriers for coordinated delivery of the
essential vaccine constituents to DCs for cross-presentation of the antigens and stimulation of T-cell responses.
When applied to the skin, the microparticles penetrate into hair follicles and target the resident DCs, the
immunologically most potent cells and site for induction of efficient immune responses. The microparticle
vaccine principle can be applied to different antigen formats such as peptides and proteins, or nucleic acids
coding for the antigens.
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INTRODUCTION
Nearly all vaccines to date are administered by injection, a
painful procedure, especially for children, which bears the risk
of propagating infections when needles are re-used. Moreover,
injection often delivers the vaccine into sites that are immuno-
logically not the most active, such as muscles or subcutaneous
tissue, and thus necessitates high excess of the vaccine
components that add to the risks of adverse effects (Egemen
et al., 1998; Mitragotri, 2005). The primary target cells for
induction of immune responses are dendritic cells (DCs), which
are unique antigen processing and presenting cells that can
efficiently initiate immune responses and induce immuno-
logical memory (Steinman and Witmer, 1978; Steinman,
2007). DCs reside as sentinels of the immune system in all
tissue where they sample and process antigens and where they
sense dangerous situation via innate immune receptors, which
triggers maturation and activation of the cells, migration to
lymph nodes, and expression of costimulatory molecules for
induction of T cells (Sallusto and Lanzavecchia, 2000). These T
cells are CD4-expressing helper cells required for both
antibody and cell-mediated immunity (CMI), and CD8-
expressing effector T cells for CMI. These cellular require-
ments define the essential constituents of vaccines for induction
of CMI, which are antigens/epitopes for helper and effector
T cells, and agonists for innate pattern recognition receptors
for maturation of DCs. Only mature DCs are capable of
inducing strong cytotoxic T-cell responses and proinflam-
matory cytokines, and are resistant to immunosuppressive
factors as, e.g., those produced in tumor microenvironments
(Palucka et al., 2011). Therefore, DCs are important targets and
mediators of both prophylactic and therapeutic vaccination.
The skin is the body’s largest immune organ and is directly
in contact with the environment (Gallo and Hooper, 2012). It
has an unbroken network of DCs, Langerhans, and dermal
DCs that can both sense danger and induce immune responses
or control and silence immune responses to avoid chronic
inflammation and immune pathologies (Stoitzner, 2010;
Seneschal et al., 2012). Ideal vaccine would be designed to
target the antigens directly to these cells in the skin, best by
noninvasive application. Such topical vaccination requires
penetration of the physical barrier of the skin and the transfer
of the vaccine components to the target DCs. We had
established that particles penetrate into skin far more
efficiently than soluble compounds (Lademann et al., 2008).
The ports of entry are the hair follicles, and particles of
different sizes penetrate to different depths in the follicle. We
had tested particles with sizes ranging from 122 nm to 1mm in
diameter (Patzelt et al., 2011). With a diameter of B600 nm,
they reach deepest to B1,400mm into the hair root sheath
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area, whereas particles of B1,000 nm diameter stay above
the root sheath. To avoid disturbance of the sheath, and
because the region above the sheath, the infundibulum, is
lined with a particular dense network of DCs (Breathnach,
1963; Gilliam et al., 1998) and thus an immunologically most
active region, we explored particle carriers of 1mm diameter
for delivery of antigens to DCs cells both in vitro and in situ
through human skin.
RESULTS AND DISCUSSION
Delivery system design, conjugation of the peptides/lipopeptide
to silicon dioxide (SiO2) particles, and effect on cell viability
These principles of noninvasive delivery to DCs through skin
were combined with the immunological principles of CMI
induction to develop a topical vaccine. The particles were
prepared by a layer-by-layer technology (Peyratout and
Da¨hne, 2004) and functionalized with antigenic peptides as
model vaccine antigens, and lipopeptide ligands for innate
immune receptors (Figure 1). As antigens, we used influenza
matrix protein M158-66 GILGFVFTL (GILG) and CMV pp65595-
603 NLVPMVATV (NLVP). The activator for DCs via innate
immune receptors was the diacyl-lipopeptide Pam2Cys-
GDPKHPKSF (P2C). This synthetic lipopeptide represents the
N-terminal sequence of the 44-kDa lipoprotein LP44 of
Mycoplasma salivarium. It carries two ester-bound fatty acids
and a free amino terminus. The synthetic lipopeptide FSL-1
elicits cellular responses through Toll-like receptor 2 (TLR2)/
TLR6 heterodimers that involve downstream NF-kB activation
and cytokine release (Kang et al., 2009). The peptides and
lipopeptide were C-terminally extended by four lysine
residues and immobilized on the particles via electrostatic
interactions with the outermost polyanion layer of the
particles, which is negatively charged at pH 8.
Polymethacrylate was used as polyanion. It has a pK value
of 6.2. At pH 5, it is almost completely protonated with a
charge of near zero. At this pH, the polycation layer
underneath the polyanion layer carries sufficient positive
charges to reverse the particle surface charge (z-potential)
to positive as validated by electrophoretic measurements
(Malvern Zetasizer, Malvern Instruments, Herrenberg,
Germany). As consequence, the attractive electrostatic forces
at pH 8 are converted to repulsive forces and the tagged
peptides were efficiently released (Figure 1). The particles
were nontoxic as, among others, shown for immature DCs
generated from human peripheral blood monocytes by culti-
vation for 5 days in medium containing IL-4 and GM-CSF and
incubated with particles coated with the different components
for 2 days (Supplementary Figure S1 online).
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Figure 1. Principle of conjugation of the peptides/lipopeptides to silicon dioxide (SiO2) particles. (a) The particles are coated with a layer-by-layer (LBL) film
with a negative surface charge at pH 7.5 that binds the peptides and lipopeptides with positively charged tetralysine tags. At pH 5.5, the surface charge changes
to positive, leading to an almost complete release of the peptides from the particle surface. (b) Uptake at pH 8 and release at pH 5 of GILG and Pam2Cys
(P2C) as single component peptides (red, green) or in peptide mixture (blue, light blue). (c) Confocal laser scanning image of the GILG-Rho adsorbed to the 1mm
LBL particles at pH 8 (left fluorescence image, right transmission image). (d) Release of the adsorbed peptides from the LBL surface by pH shift from 8 to 5.
(e) Desorption of the peptide and lipopeptide from the particle surface in dependence on the pH value.
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Particles are efficiently taken up and the antigen is displayed at
the DC surface
The particles were efficiently taken up by human DCs in vitro
regardless of whether or not peptide or lipopeptide were
attached as shown by confocal fluorescence microscopy. They
were found in vesicular structures where the peptides
detached from the particles (Figure 2a and Supplementary
Figure S2 on line). To directly demonstrate cross-presentation
of the antigenic peptide by loaded DCs, we made use of
recombinant TCR-like antibodies that specifically bind the
major histocompatibility complex (MHC)/peptide complex
HLA-A*0201/GILG (Supplementary Figure S3 online). The
antibodies are designed to recognize specific human MHC-I/
peptide complexes with high affinity and, thus, can be used to
detect and quantify processed antigen at surfaces of the
antigen-presenting cells independent from T cells (Zehn
et al., 2004, 2006; Klechevsky et al., 2008; Dahan and
Reiter, 2012). They do not bind the free peptides or peptides
associated with other compounds but MHC-I of the correct
type. Bioassays that are mostly used to monitor processed
antigens cannot differentiate antigen processing and
costimulatory effects on T cells and do not allow quantifying
the amount of processed antigen bound to MHC molecules
(Labeur et al., 1999; Luft et al., 2001; Salio et al., 2001).
Applying the antibodies to particle-loaded DCs, specific
peptides carried by the particles were detected at the cell
surface associated with the MHC-I. The amounts of cross-
presented peptide on the DCs were about the same for
particles loaded with peptides alone and those with peptides
plus P2C (Figure 2b and c). The presentation of antigenic
peptides by MHC-I molecules is thus not dependent on the
TLR ligand on the cargo as it had been suggested to be the
case for MHC class II presentation (Blander and Medzhitov,
2006). As the peptides were adsorbed to the surface of the
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Figure 2. Conjugation of peptide GILG to silicon dioxide (SiO2) particles resulted in efficient cross-presentation of the GILG antigen. (a) Confocal images
of dendritic cells (DCs) loaded with particle carrying GILG (green particles and red peptide) and Pam2Cys (P2C; blue particles). The cell surface was stained
with FITC-labeled anti-MHC-I antibodies. The confocal analysis shows that internalized GILG was inside the cells in both particle-bound form and free form in
intracellular compartments of the DCs. Images were originally obtained at  1,000 total magnification and electronically zoomed. Flow cytometric analysis
showing cross-presentation of particle-bound GILG by DCs (b, c). The cross-presentation of the particle-bound GILG was blocked by treatment with (d)
cytochalasin D and (f) brefeldin A, and slightly increased by (e) chloroquine treatment. MFI, mean fluorescence intensity; MHC-I, major histocompatibility
complex I; w/o, without. *Po0.05; **Po0.01; ***Po0.001.
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particles, it could be argued that they might be released from
the particles into the medium and in this free soluble form
would bind to MHC-I molecules without intracellular
processing. To address this issue, we inhibited the
phagocytosis by treating the DCs with cytochalasin D before
adding the particles to the cell cultures. Inhibition of
phagocytosis completely abrogated the presentation of
peptides bound to particles (Figure 2d) but had no effect on
the presentation of soluble peptides. Particle-bound peptides,
thus, follow the intracellular route of antigen cross-processing
to get to the cell surface.
Cross-presentation of the antigen delivered by SiO2 particles
does not rely on endosomal acidification and involves newly
synthesized MHC-I molecules from the endoplasmic reticulum
Upon uptake, antigens enter an endocytic pathway and
progressively pass through increasingly acidic compartments.
Raising the endosomal pH reduces the proteolytic activity of
most endosomal proteases and interferes with fusion of
vesicles (Yewdell et al., 1999). We examined whether
acidification of the endosomal compartment of human DCs
was required for cross-presentation of antigenic peptides when
delivered on particles. For that, DCs were preincubated with
chloroquine (Figure 2e) or ammonium chloride
(Supplementary Figure S4 online), and then incubated with
peptide-carrying particle with or without P2C. Surprisingly,
the neutralization of endosomal pH with chloroquine did not
decrease the cross-presentation, but slightly increased it
(Figure 2e). Cross-presentation of the particle-bound peptides
apparently does not require endosomal functions dependent
on acidification such as proteolysis by proteases or endosomal
fusion for maximum efficiency. Similar results were obtained
when endosomal acidification was inhibited with ammonium
chloride (Supplementary Figure S4 online).
According to the canonical model for cross-presentation,
endocytosed or phagocytosed antigens are translocated into
the cytosol where they are degraded into antigenic peptides by
proteasomes. Epitopes generated in this process are transported
into the lumen of the endoplasmic reticulum by the transporter
associated with antigen processing loaded onto nascent MHC-I
molecules for presentation at the cell surface (Kovacsovics-
Bankowski and Rock, 1995; Norbury et al., 1995; Reis e Sousa
and Germain, 1995; Li et al., 2001). To examine whether the
cross-presentation of the particle-bound peptide involved
MHC-I molecules recycled from the cell surface or requires
access to nascent MHC-I in the endoplasmic reticulum, we
treated DCs with brefeldin A (BFA) before adding particle-
bound peptides. BFA is a fungal metabolite that disassembles
the Golgi apparatus and thereby blocks the transport of newly
synthesized MHC-I molecules from the endoplasmic reticulum
to the cell surface (Norbury, 2000). Treatment of DCs with
BFA nearly abolished the presentation of particle-bound
peptide but not of soluble peptides (Figure 2f). Vesicle
transport via the Golgi apparatus is, thus, required for cross-
presentation of particle-bound peptide. This suggests that
binding of the epitope to MHC-I molecules occurs in intracel-
lular compartments involved in export pathways that contain
newly synthesized MHC molecules, and not in recycling
vesicles. Interestingly, BFA prevented the cross-presentation
irrespective of P2C on the particles. The preference for this
canonical route of cross-presentation even when the antigen
was administered together with a TLR ligand was surprising, as
a recent study by Burgdorf et al. (2008) demonstrated that in
the presence of TLR ligand the endosomic route was favored.
The authors had observed that, following signaling via TLR and
MyD88, transporter associated with antigen processing was
selectively recruited to endocytic organelles and antigen
processing for cross-presentation directed to endosomal
compartments (Burgdorf et al., 2008).
Particle-bound P2C induced maturation of DCs and increased
the efficiency of T-cell stimulation
As only fully mature DCs are capable of inducing strong and
sustained cytotoxic immune responses (Tan JK and O’Neill,
2005; Steinman, 2007; Palucka et al., 2011), we examined
whether the particles could induce DC maturation. Particles
carrying only peptides were not able to (Figure 3a–d). How-
ever, as expected because the DCs had been shown to express
TLR2 (Supplementary Figure S5 online), when the P2C was
attached to the particles, maturation of the cells was triggered
and detectable by the upregulation of the costimulatory
molecules CD80 and CD86, the expression of the activation
marker CD83, and production of IL-12 (Figure 3a–d).
To test the immune-stimulatory capacity of DCs charged
with particle-bound peptides with or without P2C, the cells
were cultured with T cells from the same donor for 7 days.
Proliferation of peptide-specific CD8þ T cells was then
quantified by flow cytometry using peptide/HLA-A*0201
tetramers. Only fully matured DCs were able to stimulate
proliferation of the peptide-specific CD8þ T cells (Figure 3e
and f). DCs that had not been exposed to P2C and therefore
remained immature were not capable of inducing T-cell
proliferation despite carrying the same levels of MHC-I/
peptide complexes as the mature DCs. Matured DCs also
induced strong IFN-g secretion by the T cells (Figure 3g).
Interestingly, for some donors better expansion of peptide-
specific CD8þ T cells was observed when the cognate
peptide was coupled with TLR ligand to the same particles,
whereas for other donors better stimulation was achieved
when peptide and P2C were on separate particles.
SiO2 particles reach the hair follicles and deliver the antigen to
the resident DCs
To test skin penetration of the particle vaccines, we labeled
the particles with Cy5 and loaded them with Rhodamine-
labeled peptides. The particles were massaged onto porcine
ears by standardized conditions and left for 1 and 24 hours,
respectively. After this time, punch biopsies were taken and
cryofixed. Sections of 10mm were prepared and then analyzed
by laser scan fluorescence microscopy for the penetration
depths of the blue fluorescence (Cy5) of the particles and red
fluorescence (Rhodamine) associated with the peptides. After
1 hour, the particles were detected in the hair follicles up to a
depth of 151.1±47.1mm, the peptide penetrated further to
509.1±144.2mm. After 24 hours, an average penetration
depth of 259.1±92.7mm was found for the particles and
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631.2±182.4mm for the peptide (Figure 4a). The results show
that the peptides reach the target region at the infundibulum
between 400 and 600mm (Vogt et al., 2007) already after
1 hour. Detection of peptides and particles at different depths
in the hair follicles indicated release of the peptide in the
follicle presumably triggered by a lower pH compared with
the carrier gel into which the particles had been formulated.
The follicles serve as depots for the particle vaccines.
Using human calf skin in situ, fluorescein-labeled particles
were applied and the fluorescence monitored over 10 days
in the follicles and in stratum corneum. Already after 1 day,
the particles at the stratum corneum were nearly gone,
likely shed off through contact with the fabric of the
cloths. In contrast, in the hair follicles a considerable
fraction of the particles still prevailed after 10 days
(Figure 4b). To finally test the delivery of particle-bound
antigenic peptides to DCs of the skin, we prepared particles
with Rhodamine-labeled GILG peptide and applied them
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Figure 3. Particle-bound Pam2Cys (P2C) induced maturation of dendritic cells (DCs) and increased the efficiency of T-cell stimulation. Particles carrying P2C
induced upregulation of (a) CD80, (b) CD83, (c) CD86 expression, and (d) higher levels of IL-12 secretion by DCs compared with DCs incubated with particles
without P2C. Flow cytometry profiles showing that DCs exposed to particle-bound P2C were more efficient in inducing (e) GILG- and (f) NLVP-specific CD8þ T
cells than DCs exposed to particles without P2C. The analyses shown in e and f were performed on cells from different donors. (g) The activated T cells also
produce high amounts of the immune-regulating and effector cytokine IFN-g. MFI, mean fluorescence intensity; w/o, without.
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to excised human skin of a HLA-A*0201-positive donor. HLA-
A*0201 is the specific antigen-presenting MHC-I molecule for
GILG. After thoroughly cleansing the skin to remove surface-
associated particles and peptide, the skin was minced and
dissociated by trypsin digestion. The resulting suspension was
filtered and DCs isolated with magnetic beads with anti-CD1c
antibodies (Figure 4c). The isolated DCs were analyzed by
confocal laser scanning microscopy for the fluorescence
associated with the vaccine peptide. A high proportion of
the DCs (77.7%) was found to be positive for the peptide
(Figure 4d), demonstrating an efficient delivery of the peptide
to the DCs of the skin. The calf region used in this study was
chosen because of its large hair follicles, which favors the
application of the vaccine formulation onto this area. How-
ever, the scalp could also be considered for that, once it
displays a high follicular density. The validation of the
application area is an important issue that will be addressed
in further studies.
Taken together, the experiments reported here demonstrate
that layer-by-layer–coated SiO2 particles are efficient carriers
for the delivery of vaccine antigens into the cross-presentation
pathway in human DCs. When the antigen is administered
together with TLR agonists as adjuvant, the DCs undergo full
maturation and efficiently trigger specific CD8þ T-cell activa-
tion. Application of peptide carrying particles to the skin
results in their penetration into hair follicles to a depth
controlled by the size of the particles. The particles are
retained in the follicle as a depot for several days. Antigenic
peptides coupled to the particles are efficiently delivered to
DCs of the skin. Microparticles appear to be suitable carriers
for topical vaccines for induction of CMI.
MATERIALS AND METHODS
Peptides, lipopeptides, and peptide-loaded particles
The peptides influenza matrix protein M158–66 GILGFVFTL-KKKK
(GILG) and CMV pp65595-603 NLVPMVATV-KKKK (NLVP) as well as
diacyl-lipopeptide Pam2Cys-GDPKHPKSF-KKKK (P2C) were synthe-
sized with C-terminal tetralysine tags. Fully automated solid-phase
peptide synthesis and Fmoc/tBu chemistry on TCP resin were applied.
For coupling of amino acids, a 7-fold molar excess of single Fmoc-L-
amino acids was used. The peptide resin carrying the sequence
GDPKHPKSFKKKK was elongated with the unusual amino acid
Fmoc-Dhc (Dhc: S-2,3-dihydroxy-2-(R,S)-propyl-(R)-cysteine) fol-
lowed by O-palmitoylation and Fmoc deprotection (Metzger et al.,
1991). The coupling was carried out in DMF/CH2Cl2 (1:1) with DIC/
HOBt in 3-fold excess within 3 hours and was monitored by Kaiser
assay. The peptides and the lipopeptide were cleaved off the resin by
treatment of the resin with trifluoroacetic acid/phenol/ethanedithiol/
thioanisole (96:2:1:1) for 3 hours. Trifluoroacetic acid was removed in
vacuum and the products were precipitated from cold diethylether.
The precipitate was washed three times with cold diethylether and
the pellets were dissolved in tert-butyl alcohol/water 4:1, lyophilized,
and purified by preparative HPLC. The structural characterization of
the products was carried out by HPLC/electrospray ionization mass
spectrometry. Peptides and lipopeptide were attached to layer-by-
layer-coated silica beads of 1mm diameter via negative charges on the
outermost polymer layer, as previously described (Peyratout and
Da¨hne, 2004).
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Figure 4. Penetration of the particles into hair follicle. (a) After application of fluorochrome Cy5-labeled particles coated with Rhodamine-labeled peptides to
porcine skin, the fluorescence associated with the particles (left panel) and peptides (right panel) was detected by confocal laser scanning microscopy. The
penetration depths are indicated with arrows. (b) Fluorochrome-labeled particles were applied to human calf skin and the fluorescence measured at the indicated
time points. The values were normalized to the fluorescence determined after 30 minutes as starting value. (c) Illustration of the distribution of dendritic cells in the
skin and hair follicles of human skin and of the experiments to determine delivery to cutaneous dendritic cells of antigenic peptides administered on particles. (d)
After applying particles carrying Rhodamine-labeled peptides to excised human skin, the skin was dissociated and the dendritic cells isolated by magnetic bead
separation. The isolated cells were then analyzed for the fluorescence associated with the peptides by confocal laser scanning microscopy. The left panel shows
bright field image of isolated cells and the right panel shows fluorescence detection on the cells.
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DC generation and loading
DCs were generated from peripheral blood mononuclear cells using a
protocol from Schuler et al. (1995) with minor modifications. Briefly,
peripheral blood mononuclear cells from healthy donors were
isolated from buffy coats by Ficoll gradient centrifugation. Cells of
the interface were collected and plated in six-well plates. Monocytes
were allowed to adhere. After 2 hours, non-adherent cells were
washed off and the adherent cells cultured for 7 days in RPMI-1640
culture medium (Invitrogen, Carlsbad, CA) with 10% heat-inactivated
fetal calf serum (Biochrom, Berlin, Germany). The cells were supplied
with the cytokines GM-CSF (50 ng ml 1; R&D Systems, Minneapolis,
MN) and IL-4 (50 ng ml 1; R&D Systems) on days 0 and 4 of the
culture. The cultures were kept in a CO2 incubator in a humidified
atmosphere with 8% CO2 at 37 1C. On day 5, particle-bound
peptides as indicated or an inflammatory cytokine cocktail of IL-1b
(10 ng ml 1), IL-6 (25 ng ml 1), tumor necrosis factor-a (10 ng ml 1;
all from Strathmann Biotech, Hamburg, Germany) were added and
the culture continued (Supplementary Table S1 online). In some
experiments, soluble peptides were used as indicated in the respec-
tive figures. Where inhibitors were used, cells were incubated for
2 hours at 37 1C with the respective inhibitor before addition of
particle-bound or soluble peptides. The specific inhibitors used were
cytochalasin D at 5mM, chloroquine at 50mM (both from Sigma-
Aldrich, Steinheim, Germany), ammonium choride at 50 nM (Merck,
Darmstadt, Germany), BFA at 10mM (Sigma-Aldrich). Cells were
harvested on day 7 and analyzed by flow cytometry or used for
co-cultures with T cells.
The use of human cells for the reported study was reviewed and
approved by the institutional ethics committee of the Charite´–
Universita¨tsmedizin Berlin (EA1/148/08).
Confocal microscopy for the uptake of particles by DCs
To examine the uptake of the particles by DCs and the intracellular
localization of the peptides, cells were transferred to 5 ml plastic
tubes and fixed in 1% paraformaldehyde solution for 20 minutes. The
cell membrane was stained with FITC-labeled anti-b-microglobulin
(BD Pharmingen, Heidelberg, Germany) for 25 minutes at 4 1C.
The intracellular localization of the particles or peptides carried by
the particles was analyzed by scanning confocal microscopy (Leica
TCS SP2, Leica, Wetzlar, Germany). All images were analyzed and
processed using the Leica Confocal Software Version 2.5 Build 1227.
Flow cytometry
To determine DC states and activation, the cell suspensions were
labeled with fluorescent monoclonal antibodies against Lin (cocktail
of FITC-conjugated antibodies against the molecules CD3, CD14,
CD19, and CD56) for exclusion of non-DCs, CD11c, CD80, CD83,
CD86, HLA-DR (BD Bioscience, Chicago, IL), and TLR2 (BioLegend,
San Diego, CA). For the detection and quantification of the com-
plexes HLA-A*0201/GILG at the DC surface, the cells were labeled
with the purified Fab against such a complex (clone M1D12)
(Biddison et al., 2003; Kang et al., 2009) followed by staining with
FITC-labeled secondary polyclonal antibody against human F(ab´)2
(AbCam, Cambridge, UK). T lymphocytes were labeled with antibody
for CD8 and HLA-A*0201/GILG or HLA-A*0201/NLVP tetramers
(both from Beckman Coulter, Fullerton, CA). Proliferation of the
specific CD8þ T cells was determined by flow cytometry after
incubation of these cells with the differently treated DCs. All
stained cells were analyzed with a FACSCalibur flow cytometer
(Becton Dickinson, San Jose, CA). The data were processed and
displayed using the CellQuest software (Becton Dickinson) or
WinMDi (Purdue University, West Lafayette, IN; www.purdue.edu).
ELISA for IL-12p70 and IFN-c
The supernatants of the DC cultures were collected after 48 hours of
incubation with the indicated stimuli and stored at  20 1C. The
supernatants of the cocultures of DCs and CD8þ T cells were
collected after 7 days of culture. IL-12p70 levels from the DC cultures
and IFN-g from the cocultures were measured by ELISA Max Standard
kit (BioLegend) in 96-well microtiter plates according to the manu-
facturer’s instructions. Results are expressed as pg ml 1.
Cell viability assay
Cell viability was assessed by staining the cells with a commercial kit
for discrimination of live and dead cells (Invitrogen) by flow cytometry.
The staining procedures were carried out following the manufacturer’s
instruction. Briefly, the cell suspension containing DCs was labeled
with calcein-AM and ethidium homodimer-1 and the cells were then
analyzed by flow cytometry. Cells positive for calcein were con-
sidered live and those positive for ethidium were considered dead.
CD8þ T lymphocyte proliferation assay
Total CD8þ T lymphocytes were isolated from peripheral blood by
magneto sorting. First, CD8þ T cells were isolated from the
peripheral blood mononuclear cells by positive selection using a
commercial kit (Invitrogen) following the manufacturer’s instruction.
Then, the cells were washed twice in phosphate-buffered saline and
cultured together with the autologous DCs in 96-well plates of
1 104 DCs with 2 105 T lymphocytes for 7 days, and then
harvested and analyzed by flow cytometry.
Porcine skin samples, particle application, and penetration
measurement
The follicular penetration depth of the particles was assessed in
porcine ear skin. The porcine ears used in this study were obtained
directly from the butcher from freshly slaughtered pigs. Before the
experiments were carried out, the porcine ears were rinsed with cold
water, dried with paper towels, and then the bristles were carefully
shortened. The experiments with the animal samples were performed
with approval by the Governmental Office of Veterinary Medicine in
Berlin-Treptow, Germany.
The application of the particles onto the porcine skin and the
penetration measurement were carried out as described previously
(Vogt et al., 2007). Briefly, 2 mg cm 2 of the preparation containing
the Cy5-labeled particles carrying the Rhodamine-labeled peptide
(GILGFVFTL-KKKK) was applied homogeneously onto a defined areas
of the porcine ear skin using a massage appliance for 3 minutes
(Massage Gera¨t PC60, Petra electric, Burgau, Germany). At least five
porcine ears were used. Following a penetration time of 1 or
24 hours, 3 mm punch biopsies were taken. The biopsies were
shock-frozen in liquid nitrogen and 10mm thick cryosections were
prepared. The sections were analyzed by laser scanning confocal
fluorescence microscopy for the penetration depths of the blue
fluorescence (Cy5) associated with the particles and red
fluorescence (rhodamine) associated with the peptides. A laser
scanning microscope LSM 2000 (Carl Zeiss, Jena, Germany) was
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used for the analyses. By overlapping the images, the penetration
depths of the fluorescent particles and peptides were determined. For
statistically sound data, at least 25 hair follicles were investigated.
Investigation of follicular penetration of the particles in vivo in
the human skin by ‘‘differential stripping’’
The follicular penetration of fluorescein-labeled particles was inves-
tigated at different time points. Skin samples were taken at 30 min-
utes, and 1, 4, 8, and 10 days after topical application of the particles.
Five adjacent skin areas of 4 4 cm (A–E) of the calf region of
volunteers were marked with a permanent marker. Volunteers had
signed an informed consent form approved by the Institutional Ethics
Committee of the Medical Faculty of the Charite´–Universita¨tsmedizin
Berlin (Germany) and in accordance with the ethical rules stated in
the Declaration of Helsinki Principles. The hair were removed with
scissors and the skin was rinsed with water and carefully dried with
paper towels. Subsequently, 2 mg cm 2 of an aqueous solution
containing 1% (wt/v) fluorescein-labeled particles was applied onto
the marked skin area. Skin sampling was performed from skin area A
at 30 minutes after application and from skin areas B, C, D, and E at 1,
4, 8, and 10 days, respectively, after application by differential
stripping as previously described (Teichmann et al., 2005).
Differential stripping combines the tape stripping method with the
cyanoacrylate skin surface biopsy and affords selective determination
of intercellular and follicular penetration in vivo. Tape stripping
removes the part of the stratum corneum that contained the topically
applied dye. First, the stratum corneum was removed layer by layer
by tape stripping with an adhesive film (teas No. 5529, Beiersdorf,
Hamburg, Germany). Each tape strip was pressed onto the skin with a
roller to minimize the influence of skin furrows and wrinkles. The
procedure was repeated until no more fluorescein was detectable in
the stratum corneum as controlled by laser scanning microscope
(LSM 2000, Carl Zeiss). Subsequent to the removal of the necessary
tape strips, a drop of cyanoacrylate superglue (UHU, Bru¨hl, Germany)
was placed on the stripped skin areas. The glue was covered with a
glass slide under slight pressure. After 5 minutes, the polymerized
cyanoacrylate was removed together with the glass slide with one
quick movement. These cyanoacrylate skin biopsies contained the
content of the hair follicles.
For quantification, the tape strips and the cyanoacrylate skin
surface biopsies were dissolved separately in ethanol (Uvasol, Merck,
Darmstadt, Germany) in an ultrasonic bath (Sonorex Super RK 102H,
Bandelin Electronic, Berlin, Germany). The concentration of fluor-
escein was determined by fluorescence spectrometry (Luminescent LS
50B, PerkinElmer, U¨berlingen, Germany). Excitation was at 450 nm
and the fluorescence signal measured with a spectral filter covering
the wavelength between 480 and 600 nm. The maximum fluores-
cence signal was detected at 510 nm. The intensity of the fluores-
cence signal was used as a measure of the concentration of the
fluorescent dye. The intensity is given in relative units normalized to
the values for the first time point at 30 minutes.
Human skin samples and topical particle application
Human skin (retroauricular region, breast, and abdomen) was
obtained from healthy volunteers undergoing plastic surgery within
4–24 hours after surgical excision. Volunteers had signed an informed
consent form approved by the Institutional Ethics Committee of the
Medical Faculty of the Charite´–Universita¨tsmedizin Berlin (Germany)
and in accordance with the ethical rules stated in the Declaration of
Helsinki Principles. Skin samples were examined macroscopically and
microscopically for tissue damage. Only intact skin explants were
used for transcutaneous particle penetration experiments. Skin samples
were stretched on expanded polystyrene sheets, previously covered
with aluminum foil and laboratory packaging film, and placed in a
humidified chamber that consisted of a box provided with wet napkin
paper and a cover in order to prevent skin dehydration. A volume of
20ml cm2 containing particles coated with Rhodamine-labeled peptide
(GILGFVFTL-KKKK) was applied to the excised human skin and the
chamber was placed for 16 hours in an incubator at 37 1C, 5% CO2,
and 100% humidity. This experimental setup efficiently prevented the
evaporation of the particle dispersing phase and drying of the skin.
After incubation, adhesive tape stripping was performed five times to
remove the particles that had not penetrated. The skin samples were
then processed to isolate the Langerhans DCS as described below.
Isolation of epidermal Langerhans DCs from the skin explants
Skin samples (16 cm2) were cut into 3 mm2 slices and were digested
with Dispase (2.4 U ml 1 Dispase I, Roche, Mannheim, Germany) for
2.5 hours at 37 1C to detach the epidermis layers. Trypsin digestion
(0.025% trypsin, 1.5 mM CaCl2 in phosphate-buffered saline) of the
epidermis was then performed over 15 minutes to isolate epidermal
cells. After filtration, the cells were collected by centrifugation. Subseq-
uently, MACS separation with anti-CD1c antibodies was performed on
the isolated epidermal cell according to the manufacturer’s instructions
(Dendritic Cell Isolation Kit, Miltenyi Biotec, Bergisch Gladbach,
Germany). The presence of the peptide (Rhodamine-labeled) at the
cell surface was then analyzed by laser scan fluorescence microscopy
using a laser scanning microscope LSM 2000 (Carl Zeiss).
Statistical analysis
Results were tested for normality by Kolmogorov–Smirnov tests.
Comparisons of the results obtained from the different experimental
groups were done by t-test. Differences with a Po0.05 were
considered significant. All statistical analyses were performed using
the Graphpad Software Prism 2.01 for Windows (GraphPad Software,
La Jolla, CA).
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